In vitro activities of tachyplesin III against Pseudomonas aeruginosa

Peptides

Volumn 28, Issue 4, 2007, Pages 747-751

  Cirioni, Oscar ^a   Giacometti, Andrea ^a   Kamysz, Wojciech ^b   Silvestri, Carmela ^a   Riva, Alessandra ^a   Vittoria, Agnese Della ^a   Abbruzzetti, Alessandra ^a   Łukasiak, Jerzy ^b   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Antiendotoxin activity; Antimicrobial activity; P. aeruginosa; Tachyplesin III

Indexed keywords

TACHYPLESIN; TACHYPLESIN III; UNCLASSIFIED DRUG;

ARTICLE; BACTERIUM ISOLATE; CYTOTOXICITY; DRUG ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CEFTAZIDIME; CELL LINE, TUMOR; CELL SURVIVAL; CIPROFLOXACIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PEPTIDES, CYCLIC; PSEUDOMONAS AERUGINOSA;

PSEUDOMONAS AERUGINOSA;

EID: 33847398715     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.01.001     Document Type: Article

References (32)

1. Boman H.G. Antibacterial peptides: basic facts and emerging concepts. J Intern Med 254 (2003) 197-215
2. Cannon M. A family of wound healers. Nature 328 (1987) 478
3. Carmeli Y., Troillet N., Eliopoulos G.M., and Samore M.H. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 43 (1999) 1379-1382
4. Chamot E., Boffi El Amari E., Rohner P., and Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 47 (2003) 2756-2764
5. Christensen T. Qualitative test for monitoring coupling completeness in solid phase peptide synthesis using chloranil. Acta Chem Scand Ser B (Org Chem Biochem) 33 (1979) 763-766
6. Clinical Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6 (2003), Clinical and Laboratory Standards Institute (CLSI), Villanova, PA
7. Darveau R.P., Cunningham M.D., Seachord C.L., Cassiano-Clough L., Cosand W.L., Blake J., et al. β-Lactams antibiotics potentiate magainin 2 antimicrobial activity in vitro and in vivo. Antimicrob Agents Chemother 35 (1991) 1153-1159
8. Dhople V., Krukemeyer A., and Ramamoorthy A. The human Beta-defensin-3, an antibacterial peptide with multiple biological functions. Biochim Biophys Acta 1758 (2006) 1499-1512
9. Doherty T., Waring A.J., and Hong M. Peptide-lipid interactions of the beta-hairpin antimicrobial peptide tachyplesin and its linear derivatives from solid-state NMR. Biochim Biophys Acta 1758 (2006) 1285-1291
10. Drabick J.J., Bhattacharjee A.K., Hoover D.L., Siber G.E., Morales V.E., Young L.D., et al. Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent. Antimicrob Agents Chemother 42 (1998) 583-588
11. Eliopoulos G.M., and Moellering Jr. R.C. Antimicrobial combinations. In: Lorian V. (Ed). Antibiotics in laboratory medicine. 4th ed. (1996), Williams & Wilkins, Baltimore 330-396
12. Epand R.F., Ramamoorthy A., and Epand R.M. Membrane lipid composition and the interaction of pardaxin: the role of cholesterol. Protein Pept Lett 3 (2006) 1-5
13. Falagas M.E., and Kasiakou S.K. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 40 (2005) 1333-1341
14. Giacometti A., Cirioni O., Kamysz W., D'Amato G., Silvestri C., Del Prete M.S., et al. In vitro activity of histatins derivative P-113 alone and in combination with antimicrobial agents against multidrug-resistant pathogens responsible of pneumonia in immunocompromised patients. Antimicrob Agents Chemother 49 (2005) 1249-1252
15. Gough M., Hancock R.E., and Kelly N.M. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 64 (1996) 4922-4927
16. Hancock R.E.W., and Chapple D.S. Peptide antibiotics. Antimicrob Agents Chemother 43 (1999) 1317-1323
17. Hancock R.E.W., and Scott M.G. The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci USA 97 (2000) 8856-8861
18. Hirakura Y., Kobayashi S., and Matsuzaki K. Specific interactions of the antimicrobial peptide cyclic β-sheet tachyplesin I with lipopolysaccharides. Biochim Biophys Acta 1562 (2002) 32-36
19. Holzheimer R.G. Antibiotic induced endotoxin release and clinical sepsis: a review. J Chemother 1 (2001) 159-172
20. Hsueh P.R., Chen W.H., and Luh K.T. Relationship between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents 26 (2005) 463-472
21. Iwagaki A., Porro M., and Pollack M. Influence of synthetic antiendotoxin peptides on lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14. Infect Immun 68 (2000) 1655-1663
22. McCafferty D.G., Cudic P., Yu M.K., Behenna D.C., and Kruger R. Synergy and duality in peptide antibiotic mechanisms. Curr Opin Chem Biol 3 (1999) 672-680
23. McPhee J.B., and Hancock R.E. Function and therapeutic potential of host defense peptides. J Pept Sci 11 (2005) 677-687
24. Micol J.B., de Botton S., Guieze R., Coiteux V., Darre S., Dessein R., et al. An 18-case outbreak of drug-resistant Pseudomonas aeruginosa bactieremia in hematology patients. Haematologica 91 (2006) 1134-1138
25. Moon J.-Y., Henzler-Wildman K., and Ramamoorthy A. Expression and purification of a recombinant LL-37 from Escherichia coli. Biochim Biophys Acta 1758 (2006) 1351-1358
26. Mouton J.W., den Hollander J.G., and Horrevorts A.M. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Antimicrob Chemother 31 (1993) 919-926
27. Muta T., Fujimoto T., Nakajima H., and Iwanaga S. Tachyplesins isolated from hemocyte of Southeast Asian horseshoe crabs (Carcinoscorpius rotundicauda and Tachypleus gigas): identification of a new tachyplesin, tachyplesin III, and a processing intermediate of its precursor. J Biochem 108 (1990) 261-266
28. Nakamura T., Furunaka H., Miyata T., Tokunaga F., Muta T., Iwanaga S., et al. Tachyplesin, a class of antimicrobial peptide from the hemocytes of horseshoe crab (Tachypleus tridentatus). J Biol Chem 263 (1988) 16709-16713
29. Ramamoorthy A., Thennarasu S., Tan A., Gottipati K., Sreekumar S., Heyl D.L., et al. Deletion of all cysteines in tachyplesin I abolishes emolytic activity and retains antimicrobial activity and lipopolysaccharide selective binding. Biochemistry 45 (2006) 6529-6540
30. Vaara M., and Porro M. Group of peptides that act synergistically with hydrophobic antibiotics against Gram-negative enteric bacteria. Antimicrob Agents Chemother 40 (1996) 1801-1805 [erratum in Antimicrob Agents Chemother 1997;41:496]
31. Yeaman M.R., and Yount N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 55 (2003) 27-55
32. Yethon J.A., and Whitfield C. Lipopolysaccharide as a target for the development of novel therapeutics in Gram-negative bacteria. Curr Drug Targets Infect Disord 1 (2001) 91-106